神经基因公司 NGNE
$25.31 −$0.34 (-1.33%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $25.31 0.00%
开盘$26.33
昨收$25.65
当日区间$24.68 – $27.26
成交量324.9K
市值$506.49M
市盈率（TTM）–
股息率–
NGNE 相关新闻
匹配 Neurogene 或代码 NGNE 的头条新闻，按最新排序。
- Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
- H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $65 负面
- CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $166 负面
- A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166
- LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $65 正面
- LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
- H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $70
- William Blair Maintains Neurogene(NGNE.US) With Buy Rating
- Guggenheim Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $69
- A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180
- Rodman & Renshaw Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $70
- LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $60
- Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)
- Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating, Announces Target Price $65
- CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $180
暂无评论——快来第一个聊聊 NGNE。
登录后参与讨论。